Shown to be highly effective in strengthening bones and protecting against fractures in all key sites, including hip and spine[1] Once-yearly dosing provides potential for compliance benefits and long ...

Once-yearly Aclasta Recommended In EU To Treat Male Osteoporosis And Reduce Risk Of New Fractures In Patients After Hip Fracture Male indication important as osteoporosis often neglected in men - ...

Aclasta reduced the risk of new spine fractures by 52% over six years versus patients who stopped treatment after three years[1] New data from six-year study validate Aclasta safety profile and ...

01 February 2009Single-dose therapy given once a year shown to provide significant bone protection benefits and may improve long-term treatment compliance Amman - Jordan - Aclasta (zoledronic acid 5 ...

Aclasta, which is administered by once-yearly infusion, was approved in the EU in October 2007 for the treatment of osteoporosis in postmenopausal women. It is now approved in more than 80 countries ...

Patients in the UK will this week get access to Novartis’ annual postmenopausal osteoporosis drug Aclasta, following its European approval last Friday. Patients in the UK will this week get access to ...

New long-term data for Novartis’ once-yearly osteoporosis jab Aclasta/Reclast have cemented its safety and efficacy profile, showing that the drug preserves bone mass and slashes the risk of new spine ...

ZURICH (Reuters) - Novartis AG's Aclasta was more effective than Procter & Gamble Co's Actonel in increasing bone mass in patients with the bone-thinning disease osteoporosis, a study showed. A ...

LONDON (MarketWatch) -- Swiss drugmaker Novartis said Friday that its Aclasta medicine has been approved in the European Union to treat men and postmenopausal women with osteoporosis caused by ...

April 25, 2005 — Health Canada has approved levonorgestrel emergency contraceptive for sale without a prescription to women aged 16 years and older, and an oral spray derived from components of the ...

From the good news, bad news file: Novartis got the EU's approval to sell its new osteoporosis drug Aclasta, known in the U.S. as Reclast. Reclast got the FDA's nod six weeks ago, and analysts are ...

Novartis tapped MRM Worldwide, an interactive and relationship marketing company, to undertake European patient communications for its Aclasta CRM program, it was announced yesterday. Aclasta is an ...